▎WuXiEdited by Kant Content Team

Bristol Myers Squibb recently announced that the European Medicines Agency (EMA) has accepted the extension application for its Opdivo (nivolumab) subcutaneous injection formulation, intended for all previously approved Opdivo adult solid tumor indications, including monotherapy, monotherapy maintenance after combination with Yervoy (ipilimumab), or in combination with chemotherapy or cabozantinib. The application also includes the latest dosage form of Opdivo (600 mg/vial). The centralized review procedure by the EMA has now begun.

The submission of this application is primarily based on data from the Phase 3 CheckMate-67T study. CheckMate-67T is a randomized, open-label Phase 3 clinical trial evaluating the efficacy of a subcutaneous formulation of Opdivo, co-formulated with Halozyme's proprietary recombinant human hyaluronidase rHuPH20, compared to intravenous Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have previously received systemic therapy.PreviouslyThe press release stated that the Opdivo subcutaneous formulation can be administered in a single injection within 5 minutes, which is expected to transform the treatment experience for patients and doctors.

The analysis shows,The trial met its primary endpoint, demonstrating non-inferiority for subcutaneous Opdivo compared to intravenous Opdivo in terms of average serum concentration over 28 days (Cavgd28) and steady-state serum trough concentration (Cminss).Moreover, as assessed by Blinded Independent Central Review (BICR), the subcutaneous formulation demonstrated non-inferiority in Objective Response Rate (ORR) compared to intravenous Opdivo, which is a key secondary endpoint.

In terms of safety, the safety of the Opdivo subcutaneous formulation is consistent with the intravenous formulation.

Opdivo is a PD-1 immune checkpoint inhibitor designed to harness the body's own immune system to help restore anti-tumor immune responses.Opdivo has become an important treatment option across multiple types of cancer. To date, the Opdivo clinical development program has treated more than 35,000 patients.

References:

[1] U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase). Retrieved May 6, 2024 from https://news.bms.com/news/corporate-financial/2024/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Application-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx

Disclaimer:The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.

Copyright Statement: This article is from the WuXi AppTec content team. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.